Skip to main content
A

AFT Pharmaceuticals Limited — Investor Relations & Filings

Ticker · AFT ISIN · NZAFTE0001S4 NZX Manufacturing
Filings indexed 318 across all filing types
Latest filing 2024-04-30 Regulatory Filings
Country NZ New Zealand
Listing NZX AFT

About AFT Pharmaceuticals Limited

https://www.aftpharm.com

AFT Pharmaceuticals Limited focuses on the development, licensing, and distribution of pharmaceutical products across a broad range of therapeutic categories. The company’s core portfolio includes pain management, dermatology, eye care, and hospital-based medicines. Its flagship product, Maxigesic, is a patented combination of paracetamol and ibuprofen available in multiple dosage forms and marketed globally. AFT Pharmaceuticals emphasizes research and development to create innovative delivery systems and therapeutic solutions. The company operates through a combination of direct sales in specific regions and international licensing agreements, reaching markets in over 100 countries. Its product range spans over-the-counter (OTC) and prescription medications, targeting both retail pharmacy and clinical environments.

Recent filings

Filing Released Lang Actions
AFT Licenses Maxigesic(R) IV in Brazil
Regulatory Filings
2024-04-30 English
AFT,Massey Ventures,Gilles McIndoe to develop scar treatmen
Regulatory Filings
2024-04-23 English
AFT makes further progress in international markets
Regulatory Filings
2024-03-03 English
AFT updates operating profit guidance to $23m to $25m
Regulatory Filings
2024-02-15 English
Maxigesic IV launched in the United States
Regulatory Filings
2024-02-06 English
AFT further broadens R&D pipeline with new product
Regulatory Filings
2024-01-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.